Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

JN Brudno, N Lam, D Vanasse, Y Shen, JJ Rose… - Nature medicine, 2020 - nature.com
JN Brudno, N Lam, D Vanasse, Y Shen, JJ Rose, J Rossi, A Xue, A Bot, N Scholler
Nature medicine, 2020nature.com
Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells are an effective treatment for
B-cell lymphoma, but often cause neurologic toxicity. We treated 20 patients with B-cell
lymphoma on a phase I, first-in-human clinical trial of T cells expressing the new anti-CD19
CAR Hu19-CD828Z (NCT02659943). The primary objective was to assess safety and
feasibility of Hu19-CD828Z T-cell therapy. Secondary objectives included assessments of
blood levels of CAR T cells, anti-lymphoma activity, second infusions and immunogenicity …
Abstract
Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells are an effective treatment for B-cell lymphoma, but often cause neurologic toxicity. We treated 20 patients with B-cell lymphoma on a phase I, first-in-human clinical trial of T cells expressing the new anti-CD19 CAR Hu19-CD828Z (NCT02659943). The primary objective was to assess safety and feasibility of Hu19-CD828Z T-cell therapy. Secondary objectives included assessments of blood levels of CAR T cells, anti-lymphoma activity, second infusions and immunogenicity. All objectives were met. Fifty-five percent of patients who received Hu19-CD828Z T cells obtained complete remission. Hu19-CD828Z T cells had clinical anti-lymphoma activity similar to that of T cells expressing FMC63-28Z, an anti-CD19 CAR tested previously by our group, which contains murine binding domains and is used in axicabtagene ciloleucel. However, severe neurologic toxicity occurred in only 5% of patients who received Hu19-CD828Z T cells, whereas 50% of patients who received FMC63-28Z T cells experienced this degree of toxicity (P = 0.0017). T cells expressing Hu19-CD828Z released lower levels of cytokines than T cells expressing FMC63-28Z. Lower levels of cytokines were detected in blood from patients who received Hu19-CD828Z T cells than in blood from those who received FMC63-28Z T cells, which could explain the lower level of neurologic toxicity associated with Hu19-CD828Z. Levels of cytokines released by CAR-expressing T cells particularly depended on the hinge and transmembrane domains included in the CAR design.
nature.com